At screening, blood samples are being used for several assays to test for eligibility for participation in the trial. At trial time points, blood samples will be used in assays to produce primary and secondary outcomes (i.e. data that will form the results of the trial). A urine sample will also be taken at each time point, which will be used to measure the level of viral DNA.